IL129020A - Pharmaceutical preparations containing a history of S-alkylates and uranium - Google Patents

Pharmaceutical preparations containing a history of S-alkylates and uranium

Info

Publication number: IL129020A
Authority: IL; Israel
Prior art keywords: use according; compound; medicament; formula; blood
Prior art date: 1996-09-26

Application number

IL12902097A

Other languages

English (en)

Hebrew (he)

Other versions

IL129020A0 (en

Original Assignee

Meditor Pharmaceutical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-26

Filing date

1997-09-25

Publication date

2004-06-20

1996-09-26 Priority claimed from RU96119163A external-priority patent/RU2142796C1/ru

1997-09-19 Priority claimed from RU97115433/14A external-priority patent/RU2187309C2/ru

1997-09-25 Application filed by Meditor Pharmaceutical Ltd filed Critical Meditor Pharmaceutical Ltd

2000-02-17 Publication of IL129020A0 publication Critical patent/IL129020A0/xx

2004-06-20 Publication of IL129020A publication Critical patent/IL129020A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 6
150000001875 compounds Chemical class 0.000 claims abstract description 29
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 23
229910052760 oxygen Inorganic materials 0.000 claims abstract description 23
239000001301 oxygen Substances 0.000 claims abstract description 23
208000001953 Hypotension Diseases 0.000 claims abstract description 15
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract description 9
229910052698 phosphorus Inorganic materials 0.000 claims abstract description 9
239000011574 phosphorus Substances 0.000 claims abstract description 9
239000002253 acid Substances 0.000 claims abstract description 6
208000032843 Hemorrhage Diseases 0.000 claims abstract description 5
230000000222 hyperoxic effect Effects 0.000 claims abstract description 4
231100000572 poisoning Toxicity 0.000 claims abstract description 4
230000000607 poisoning effect Effects 0.000 claims abstract description 4
230000035939 shock Effects 0.000 claims abstract description 4
UCQFCFPECQILOL-UHFFFAOYSA-N diethyl hydrogen phosphate Chemical compound CCOP(O)(=O)OCC UCQFCFPECQILOL-UHFFFAOYSA-N 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 26
230000001154 acute effect Effects 0.000 claims description 20
238000002360 preparation method Methods 0.000 claims description 19
230000004872 arterial blood pressure Effects 0.000 claims description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
125000005341 metaphosphate group Chemical group 0.000 claims description 5
PRAHMDIEZMWIRW-UHFFFAOYSA-N propyl dihydrogen phosphite Chemical compound CCCOP(O)O PRAHMDIEZMWIRW-UHFFFAOYSA-N 0.000 claims description 4
150000001450 anions Chemical group 0.000 claims description 3
NFORZJQPTUSMRL-UHFFFAOYSA-N dipropan-2-yl hydrogen phosphite Chemical compound CC(C)OP(O)OC(C)C NFORZJQPTUSMRL-UHFFFAOYSA-N 0.000 claims description 3
ZUNGGJHBMLMRFJ-UHFFFAOYSA-O ethoxy-hydroxy-oxophosphanium Chemical compound CCO[P+](O)=O ZUNGGJHBMLMRFJ-UHFFFAOYSA-O 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
JYFHYPJRHGVZDY-UHFFFAOYSA-N Dibutyl phosphate Chemical compound CCCCOP(O)(=O)OCCCC JYFHYPJRHGVZDY-UHFFFAOYSA-N 0.000 claims description 2
KKUKTXOBAWVSHC-UHFFFAOYSA-N Dimethylphosphate Chemical compound COP(O)(=O)OC KKUKTXOBAWVSHC-UHFFFAOYSA-N 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
238000002692 epidural anesthesia Methods 0.000 claims description 2
208000024891 symptom Diseases 0.000 claims description 2
CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 claims description 2
206010021118 Hypotonia Diseases 0.000 claims 2
208000007379 Muscle Hypotonia Diseases 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
125000005843 halogen group Chemical group 0.000 claims 2
YFEHFLUEQSONBX-UHFFFAOYSA-N [amino(methylsulfanyl)methylidene]azanium;dimethyl phosphate Chemical compound CSC(N)=N.COP(O)(=O)OC YFEHFLUEQSONBX-UHFFFAOYSA-N 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
208000014674 injury Diseases 0.000 claims 1
208000012866 low blood pressure Diseases 0.000 claims 1
210000000056 organ Anatomy 0.000 claims 1
AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical compound [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 claims 1
230000008733 trauma Effects 0.000 claims 1
150000003839 salts Chemical class 0.000 abstract description 5
150000007513 acids Chemical class 0.000 abstract description 3
208000011861 acute hypotension Diseases 0.000 abstract description 2
210000004369 blood Anatomy 0.000 description 64
239000008280 blood Substances 0.000 description 64
238000002347 injection Methods 0.000 description 22
239000007924 injection Substances 0.000 description 22
238000010253 intravenous injection Methods 0.000 description 21
230000007423 decrease Effects 0.000 description 18
230000000694 effects Effects 0.000 description 17
238000002844 melting Methods 0.000 description 16
230000008018 melting Effects 0.000 description 16
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 15
230000003247 decreasing effect Effects 0.000 description 14
238000002474 experimental method Methods 0.000 description 14
230000000241 respiratory effect Effects 0.000 description 14
230000001631 hypertensive effect Effects 0.000 description 13
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 12
241000282326 Felis catus Species 0.000 description 11
241001465754 Metazoa Species 0.000 description 11
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 9
238000001990 intravenous administration Methods 0.000 description 9
230000000717 retained effect Effects 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
230000000004 hemodynamic effect Effects 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
230000017531 blood circulation Effects 0.000 description 7
239000008103 glucose Substances 0.000 description 7
239000000203 mixture Substances 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
208000032456 Hemorrhagic Shock Diseases 0.000 description 6
206010049771 Shock haemorrhagic Diseases 0.000 description 6
235000012000 cholesterol Nutrition 0.000 description 6
230000002503 metabolic effect Effects 0.000 description 6
240000005578 Rivina humilis Species 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000007789 gas Substances 0.000 description 5
230000036543 hypotension Effects 0.000 description 5
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 5
229960001802 phenylephrine Drugs 0.000 description 5
208000010444 Acidosis Diseases 0.000 description 4
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
206010020772 Hypertension Diseases 0.000 description 4
206010027417 Metabolic acidosis Diseases 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000001684 chronic effect Effects 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
-1 isothiouronium diethylphosphate Chemical compound 0.000 description 4
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 4
229960001289 prazosin Drugs 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000002792 vascular Effects 0.000 description 4
RSKXYCDTGOUAKH-UHFFFAOYSA-N 2-methylpropyl dihydrogen phosphite Chemical compound CC(C)COP(O)O RSKXYCDTGOUAKH-UHFFFAOYSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
208000003098 Ganglion Cysts Diseases 0.000 description 3
208000005400 Synovial Cyst Diseases 0.000 description 3
230000001800 adrenalinergic effect Effects 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
208000034158 bleeding Diseases 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
230000036471 bradycardia Effects 0.000 description 3
208000006218 bradycardia Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
DJAWTLQJFNXUJG-UHFFFAOYSA-N diethyl phosphate ethylcarbamothioylazanium Chemical compound CC[NH+]=C(N)S.CCOP([O-])(=O)OCC DJAWTLQJFNXUJG-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
239000000644 isotonic solution Substances 0.000 description 3
230000033001 locomotion Effects 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000036387 respiratory rate Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
206010003497 Asphyxia Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
206010058490 Hyperoxia Diseases 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000000059 bradycardiac effect Effects 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
208000021822 hypotensive Diseases 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
229910052753 mercury Inorganic materials 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000036581 peripheral resistance Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000004223 radioprotective effect Effects 0.000 description 2
230000036391 respiratory frequency Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
210000001835 viscera Anatomy 0.000 description 2
VJRLOPVXROQXLO-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;urea Chemical compound NC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VJRLOPVXROQXLO-BTVCFUMJSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
AVXBTEZHGRNURI-UHFFFAOYSA-N CN=C(N)S.CN=C(N)S.COP(O)O Chemical compound CN=C(N)S.CN=C(N)S.COP(O)O AVXBTEZHGRNURI-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
206010021137 Hypovolaemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
GMEHFXXZSWDEDB-UHFFFAOYSA-N N-ethylthiourea Chemical compound CCNC(N)=S GMEHFXXZSWDEDB-UHFFFAOYSA-N 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
201000004239 Secondary hypertension Diseases 0.000 description 1
208000032450 Surgical Shock Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
GOAOYUXOJWNLSV-UHFFFAOYSA-N butylcarbamothioylazanium dibutyl phosphate Chemical compound CCCC[NH+]=C(N)S.CCCCOP([O-])(=O)OCCCC GOAOYUXOJWNLSV-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000006837 decompression Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003457 ganglion blocking agent Substances 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
229950002932 hexamethonium Drugs 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000013101 initial test Methods 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007383 nerve stimulation Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
150000002926 oxygen Chemical class 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000036513 peripheral conductance Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
206010037833 rales Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229930195734 saturated hydrocarbon Natural products 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
206010040560 shock Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000004873 systolic arterial blood pressure Effects 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002861 ventricular Effects 0.000 description 1
230000009278 visceral effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Biochemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

IL12902097A 1996-09-26 1997-09-25 Pharmaceutical preparations containing a history of S-alkylates and uranium IL129020A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
RU96119163A RU2142796C1 (ru)	1996-09-26	1996-09-26	Лекарственное противошоковое средство
RU97115433/14A RU2187309C2 (ru)	1997-09-19	1997-09-19	Средство, влияющее на артериальное давление
PCT/IL1997/000314 WO1998013036A1 (en)	1996-09-26	1997-09-25	Pharmaceutical compositions comprising s-alkylisothiouronium derivatives

Publications (2)

Publication Number	Publication Date
IL129020A0 IL129020A0 (en)	2000-02-17
IL129020A true IL129020A (en)	2004-06-20

Family

ID=26653892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12902097A IL129020A (en)	1996-09-26	1997-09-25	Pharmaceutical preparations containing a history of S-alkylates and uranium

Country Status (17)

Country	Link
US (1)	US6160008A (de)
EP (1)	EP0928191B1 (de)
JP (1)	JP4260888B2 (de)
KR (1)	KR100575507B1 (de)
CN (1)	CN1116871C (de)
AT (1)	ATE222758T1 (de)
AU (1)	AU717712B2 (de)
BR (1)	BR9712851A (de)
CA (1)	CA2266533C (de)
DE (1)	DE69715013T2 (de)
DK (1)	DK0928191T3 (de)
ES (1)	ES2182116T3 (de)
IL (1)	IL129020A (de)
NO (1)	NO326600B1 (de)
PT (1)	PT928191E (de)
TR (1)	TR199900783T2 (de)
WO (1)	WO1998013036A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2420410C (en)	2000-09-05	2011-04-26	Meditor Pharmaceuticals Ltd.	Pharmaceutical compositions for headache, migraine, nausea and emesis
WO2007029255A1 (en) *	2005-09-06	2007-03-15	Meditor Pharmaceuticals Ltd.	Prevention of hypotension and stabilization of blood pressure in hemodialysis patients
US20090186854A1 (en) *	2006-03-23	2009-07-23	Meditor Pharmaceuticals Ltd.	S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
EP2167050A1 (de) *	2007-06-13	2010-03-31	Meditor Pharmaceuticals Ltd.	Geschmacksmaskierte pharmazeutische zusammensetzungen von s-alkylisothiouronium-derivaten
MD3619G2 (ro) *	2007-11-06	2009-01-31	Рафаэль Баркан	Remediu medicamentos nazal cu acţiune anticongestivă
EA030035B1 (ru) *	2007-11-06	2018-06-29	Меламед, Лемуил	Применение s-этилизотиоурония диэтилфосфата для изготовления лекарственного средства для лечения нарушения матки
US12011423B2 (en)	2007-11-06	2024-06-18	Foraviset Ltd.	S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
CN104140386A (zh) *	2014-02-12	2014-11-12	上海应用技术学院	一种2-苄基-异硫脲三氟乙酸盐的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3123636A (en) *		1964-03-03		Thiuronium h alii
US3116327A (en) *	1960-07-22	1963-12-31	Baxter Laboratories Inc	Upsilon-dimethylaminopropyl isothiourea and acid addition salts thereof
US3657337A (en) *	1967-12-04	1972-04-18	Sandoz Ag	Benzylideneamino guanidines
FR2419675A1 (fr) *	1978-03-16	1979-10-12	Philagro Sa	Compositions fongicides a base de phosphites d'isothiouronium
AT395012B (de) *	1986-06-27	1992-08-25	Richter Gedeon Vegyeszet	Verfahren zur herstellung von n-(1(s)\|thoxycarbonyl-3-phenyl-propyl)-(s)-alanyl-(s)prolin und von dessen saeureadditionssalzen

1997
- 1997-09-25 WO PCT/IL1997/000314 patent/WO1998013036A1/en not_active Ceased
- 1997-09-25 AT AT97941178T patent/ATE222758T1/de active
- 1997-09-25 CN CN97199137A patent/CN1116871C/zh not_active Expired - Fee Related
- 1997-09-25 PT PT97941178T patent/PT928191E/pt unknown
- 1997-09-25 EP EP97941178A patent/EP0928191B1/de not_active Expired - Lifetime
- 1997-09-25 BR BR9712851-1A patent/BR9712851A/pt not_active IP Right Cessation
- 1997-09-25 US US09/269,405 patent/US6160008A/en not_active Expired - Fee Related
- 1997-09-25 DK DK97941178T patent/DK0928191T3/da active
- 1997-09-25 KR KR1019997002578A patent/KR100575507B1/ko not_active Expired - Fee Related
- 1997-09-25 JP JP51546498A patent/JP4260888B2/ja not_active Expired - Fee Related
- 1997-09-25 ES ES97941178T patent/ES2182116T3/es not_active Expired - Lifetime
- 1997-09-25 TR TR1999/00783T patent/TR199900783T2/xx unknown
- 1997-09-25 IL IL12902097A patent/IL129020A/en not_active IP Right Cessation
- 1997-09-25 AU AU43178/97A patent/AU717712B2/en not_active Ceased
- 1997-09-25 DE DE69715013T patent/DE69715013T2/de not_active Expired - Lifetime
- 1997-09-25 CA CA002266533A patent/CA2266533C/en not_active Expired - Fee Related
1999
- 1999-03-24 NO NO19991419A patent/NO326600B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
KR20000048636A (ko)	2000-07-25
NO326600B1 (no)	2009-01-19
TR199900783T2 (xx)	1999-07-21
CA2266533C (en)	2007-08-07
NO991419L (no)	1999-05-21
BR9712851A (pt)	2000-01-18
DE69715013T2 (de)	2003-05-22
US6160008A (en)	2000-12-12
AU4317897A (en)	1998-04-17
PT928191E (pt)	2003-01-31
CN1234737A (zh)	1999-11-10
KR100575507B1 (ko)	2006-05-03
DE69715013D1 (de)	2002-10-02
JP4260888B2 (ja)	2009-04-30
ES2182116T3 (es)	2003-03-01
JP2001501928A (ja)	2001-02-13
IL129020A0 (en)	2000-02-17
DK0928191T3 (da)	2002-12-30
HK1022833A1 (en)	2000-08-25
CN1116871C (zh)	2003-08-06
CA2266533A1 (en)	1998-04-02
EP0928191B1 (de)	2002-08-28
NO991419D0 (no)	1999-03-24
ATE222758T1 (de)	2002-09-15
AU717712B2 (en)	2000-03-30
EP0928191A1 (de)	1999-07-14
WO1998013036A1 (en)	1998-04-02

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-02-20	KB	Patent renewed
2007-12-03	KB	Patent renewed
2012-10-31	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
DE69533940T2 (de)	2005-12-22	Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
US4167562A (en)	1979-09-11	Method and composition for treating arteriosclerosis
CA2152487C (en)	2002-07-02	Method for treating a medical patient for cardiac trauma
JPH06504286A (ja)	1994-05-19	人ｉｇｆ−ｉの利用方法
EP0303677A1 (de)	1989-02-22	Arylcyclobutyl-derivate zur behandlung von morbus parkinson
JPH0639383B2 (ja)	1994-05-25	医薬組成物
JPS6221767B2 (de)	1987-05-14
EP0928191B1 (de)	2002-08-28	S-alkylisothiouronium-derivate enthaltende pharmazeutische zusammensetzungen
Johnson Jr et al.	1979	Unique resistance to guanethidine-induced chemical sympathectomy of spontaneously hypertensive rats: a resistance overcome by treatment with antibody to nerve growth factor.
DE69629282T2 (de)	2004-04-22	Verwendung eines pyruvatdehydrogenaseaktivators zur behandlung der ischämie in gliedern
EP1057489B1 (de)	2007-01-03	Verwendung von proteinen der midkine-familie in der behandlung von ischämischen krankheiten
RU2122415C1 (ru)	1998-11-27	Способ интенсивной терапии у больных с травматическим шоком
JPS6258336B2 (de)	1987-12-05
Runciman	1980	Sympathomimetic amines
DE2743704C2 (de)	1983-10-27	L- oder DL-Phenylglycine enthaltende Arzneimittel
RU2338538C1 (ru)	2008-11-20	Антигипотензивное средство
US8106009B2 (en)	2012-01-31	Pharmaceutical composition for preventing or treating ischemic diseases
RU2295968C2 (ru)	2007-03-27	Комбинированный препарат, обладающий седативным, спазмолитическим и противоаллергическим действием
RU2187309C2 (ru)	2002-08-20	Средство, влияющее на артериальное давление
Heard et al.	1913	A CLINICAL AND EXPERIMENTAL INVESTIGATION OF THE THERAPEUTIC VALUE OF CAMPHOR.
US4219566A (en)	1980-08-26	Phenylglyoxylic acids and derivatives thereof
Tuohy et al.	1937	A comparative study of the physiologic activity of cobefrin and epinephrine
TWI672145B (zh)	2019-09-21	預防及／或治療代謝疾病的醫藥組合物及其用途
US4239779A (en)	1980-12-16	Use of phenylglyoxylic acids and derivatives thereof in the treatment of ischemic heart disease
HK1022833B (en)	2004-03-05	Pharmaceutical compositions comprising s-alkylisothiouronium derivatives